Antiviral Drugs Companies and Strategic Expansion Initiatives

Which are the Top Companies in Antiviral Drugs Market 2026? Let's Explore

Top Companies in the Market & Their Offerings

Lonza Group AG

Headquarters: Basel, Switzerland
Offerings: Lonza provides contract development and manufacturing services (CDMO) for biologics, cell and gene therapies, vaccines, and antiviral drugs. Their services cover process development, clinical-scale manufacturing, and commercial-scale manufacturing.

Catalent, Inc

Headquarters: New Jersey, USA
Offerings: Catalent offers comprehensive drug development solutions, including oral and injectable delivery technologies, biologics manufacturing, and antiviral formulation services.

Cytiva

Headquarters: Massachusetts, USA
Offerings: Cytiva specializes in bioprocessing equipment and consumables, single-use systems, and cell culture solutions, supporting the production of antiviral drugs and vaccines.

Samsung Biologics

Headquarters: South Korea
Offerings: Samsung Biologics provides contract development and manufacturing services for biologics, focusing on monoclonal antibodies, vaccines, and antiviral therapies.

Thermo Fisher Scientific, Inc.

Headquarters: Massachusetts, USA
Offerings: Thermo Fisher supplies laboratory instruments, analytical tools, bioprocessing solutions, and materials essential for antiviral drug discovery and production.

Novartis AG

Headquarters: Basel, Switzerland
Offerings: Novartis engages in research, development, and commercialization of innovative antiviral drugs, vaccines, and therapies for infectious diseases, along with global distribution.

Value Chain Analysis

Regulatory Approvals

• Antiviral drugs undergo Phase 1, 2, and 3 clinical trials to evaluate safety, efficacy, and correct dosage.
• Applications are submitted to agencies like the FDA and EMA, sometimes starting with emergency use authorizations before full approval.
• Common mechanisms include protease inhibition and polymerase blocking to prevent viral replication, targeting diseases such as HIV, Hepatitis, Influenza, COVID-19, and RSV.
• Key players: Gilead Sciences, Pfizer, Merck & Co., Roche, AbbVie, and Johnson & Johnson.

Packaging and Serialization

• Unique codes, such as DataMatrix or QR codes, are assigned to individual drug units, including blisters, bottles, and cartons, to enable track-and-trace throughout the supply chain.
• Serialization helps prevent counterfeit products, ensuring patient safety and regulatory compliance.
• Key regulations guiding this process include the DSCSA in the United States and the FMD in the European Union.
• Key Players: Optel Group, SEA Vision, Schreiner MediPharm, Domino Printing, and Antares Vision

Patient Support and Services

• Programs ensure patients have timely access to antiviral medications and proper guidance on usage.
• Support includes managing side effects, improving treatment adherence, and providing financial or insurance assistance.
• These services are delivered through collaboration among healthcare providers, pharmacies, pharmaceutical companies, and patient advocacy organizations.
• Key Players: Gilead Sciences, Pfizer, Merck & Co., AbbVie, and Johnson & Johnson

Market Forecast

The global antiviral drugs market size was estimated at USD 62.85 billion in 2025 and is predicted to increase from USD 65.13 billion in 2026 to approximately USD 89.86 billion by 2035, expanding at a CAGR of 3.64% from 2026 to 2035.

What are the Recent Developments in the Antiviral Drugs Market?

• In December 2025, Mirum announced an up to $820 million acquisition of Bluejay Therapeutics to gain rights to a late-stage antiviral antibody for chronic hepatitis D.
• In August 2024, Apple Tree Partners invested $55 million in Red Queen Therapeutics, a biotech developing broad-spectrum antivirals targeting viruses including COVID-19 and influenza.
• In March 2024, Gilead Sciences finalized its approximately $4.3 billion acquisition of CymaBay Therapeutics following a tender offer launched in February. CymaBay became a wholly owned subsidiary, strengthening Gilead’s liver disease portfolio, particularly through the addition of seladelpar, CymaBay’s lead investigational therapy.

Partner with our experts to explore the Antiviral Drugs Market at sales@towardshealthcare.com